Disease · EFO_1001332

Giant Lymph Node Hyperplasia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Giant Lymph Node Hyperplasia. Diseases, record EFO_1001332. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001332

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Giant Lymph Node Hyperplasia; Open Targets
Open Targets ID: EFO_1001332; Open Targets
Other names: AFLH, Castleman disease, Castleman's disease, Castleman's tumor, Castleman's tumour, GLNH, angiofollicular ganglionic hyperplasia, angiofollicular lymph hyperplasia, angiofollicular lymph node hyperplasia, angiofollicular lymphoid hyperplasia; Open Targets
MeSH: D005871; MeSH
Highest stage of its drugs: Approval, for 2 of its 11 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SILTUXIMAB	CHEMBL1743070	Antibody	Approval	DailyMed and EMA Human Drugs	5	3	3	Drugs and targets
IBUDILAST	CHEMBL19449	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SURAMIN HEXASODIUM	CHEMBL413376	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
POMALIDOMIDE	CHEMBL43452	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets33

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 1/2	https://conductscience.org/library/genes/51185	Drugs and targets
CSNK2A1	Casein kinase II subunit alpha	1	Casein kinase II alpha inhibitor	Phase 1	https://conductscience.org/library/genes/1457	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 1/2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 1/2	https://conductscience.org/library/genes/1642	Drugs and targets
FGF1	Fibroblast growth factor 1	1	Acidic fibroblast growth factor inhibitor	Phase 2	https://conductscience.org/library/genes/2246	Drugs and targets
IL6	Interleukin-6	1	Interleukin-6 antagonist	Approval	https://conductscience.org/library/genes/3569	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 1/2	https://conductscience.org/library/genes/2908	Drugs and targets
PDE10A	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	1	Phosphodiesterase 10A inhibitor	Approval	https://conductscience.org/library/genes/10846	Drugs and targets

1 to 10 of 33

See all 33 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01024036	A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease	Phase 2	79	2014-08-20	Multicentric Castleman's Disease	SILTUXIMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01400503	A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease	Phase 2	60	2018-03-29	Multicentric Castleman's Disease	SILTUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04585893	Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi	Phase 2	15	2025-09-11	Multicentric Castleman Disease	ETOPOSIDE, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00412321	A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease	Phase 1	67		Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia	SILTUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00891280	Dose-escalation Study of Oral CX-4945	Phase 1	55		Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma	SILMITASERTIB	Its record names the disease	ClinicalTrials.gov
NCT02228512	Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas	Phase 1/2	0		Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma	CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, POMALIDOMIDE, PREDNISONE, RITUXIMAB, VINCRISTINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00002652	Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease	Phase 2			Multiple Myeloma and Plasma Cell Neoplasm	SURAMIN HEXASODIUM	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
High-risk Patients vs Low-risk Patients: Number of Participant With Non-hematologic Grade ≥3 Adverse Events (AEs)	0 of 9	0 of 6	15	NCT04585893	Trial comparisons
High-risk Patients vs Low-risk Patients: deaths from any cause	1 of 9	0 of 6	15	NCT04585893	Trial comparisons
High-risk Patients vs Low-risk Patients: serious adverse events	1 of 9	1 of 6	15	NCT04585893	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35793409	DERIVED	1	PubMed
28087540	DERIVED	1	PubMed
25042199	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001332

GET https://conductscience.org/api/diseases/v1/EFO_1001332/targets?page=2

API reference For AI assistants